CAMBRIDGE, Mass.--(BUSINESS WIRE)--Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) today announced positive preliminary results from an ongoing Phase 1 clinical study of Azedra (Ultratrace™ iobenguane I 131 or Ultratrace MIBG) for the treatment of malignant pheochromocytoma, a type of neuroendocrine cancer. The study, presented during a poster session at the annual meeting of the American Society of Clinical Oncology (ASCO), is the first segment of a Phase 1/2 study that is designed to assess safety and identify Azedra’s maximum tolerated dose. A Phase 2/3 portion of the trial, expected to begin in the second half of 2008, will be designed to evaluate Azedra’s antitumor efficacy.
